金吾财讯 | 基石药业－Ｂ(02616)公布截至2024年12月31日止年度之年度业绩，年内亏损9120.7万元(人民币，下同)，同比亏损收窄75.16%；每股基本亏损0.07元。不派息。期内，集团收入4.07亿元，同比减少12.21%。包括药品（阿伐替尼及普拉替尼）销售1.75亿元、授权费收入2.04亿元及舒格利单抗特许权使用费收入2810万元。授权费收入同比增加113.1%，其在很大程度上抵销了药品销售收入的减少。期内，集团毛利2.4亿元，同比减少21.08%。期内集团研发开支1.35亿元，同比减少74.49%，乃主要由于里程碑费用及第三方合约成本减少。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.